Chardan Capital Forecasts Strong Price Appreciation for Krystal Biotech (NASDAQ:KRYS) Stock

Krystal Biotech (NASDAQ:KRYS) had its price target raised by equities researchers at Chardan Capital from $212.00 to $218.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Chardan Capital’s price objective indicates a potential upside of 23.74% from the company’s previous close.

KRYS has been the subject of a number of other research reports. Citigroup raised their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. HC Wainwright reiterated a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research report on Wednesday. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $207.67.

Krystal Biotech Trading Up 12.4 %

Shares of NASDAQ:KRYS opened at $176.17 on Thursday. Krystal Biotech has a 52 week low of $107.50 and a 52 week high of $219.34. The company’s 50 day moving average is $157.40 and its two-hundred day moving average is $175.17. The company has a market cap of $5.07 billion, a PE ratio of 99.53 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping the consensus estimate of $1.29 by $0.23. The company had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm’s revenue was up 116.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.30 earnings per share. As a group, equities research analysts expect that Krystal Biotech will post 3.22 EPS for the current year.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 14.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

Hedge funds and other institutional investors have recently made changes to their positions in the business. Wilmington Savings Fund Society FSB acquired a new position in shares of Krystal Biotech during the third quarter worth about $40,000. Values First Advisors Inc. acquired a new position in Krystal Biotech during the 3rd quarter worth approximately $53,000. Huntington National Bank boosted its holdings in Krystal Biotech by 97.6% in the 3rd quarter. Huntington National Bank now owns 573 shares of the company’s stock worth $104,000 after acquiring an additional 283 shares during the period. Blue Trust Inc. grew its position in Krystal Biotech by 242.4% in the third quarter. Blue Trust Inc. now owns 582 shares of the company’s stock valued at $107,000 after acquiring an additional 412 shares in the last quarter. Finally, GF Fund Management CO. LTD. purchased a new stake in shares of Krystal Biotech during the fourth quarter valued at approximately $95,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).